Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients

doi:10.4254/wjh.v15.i8.964

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5635)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

114

WORD

HTML

2460

Figures (1-2)

482

Tables (1-3)

480

Sum=3572

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

232

Download

857

Sum=1089

Publishing Process of This Article

Item

Count

Browse

179

Download

604

Sum=783

Aug 27, 2023 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (8)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Hepatol. Aug 27, 2023; 15(8): 964-972
Published online Aug 27, 2023. doi: 10.4254/wjh.v15.i8.964

Full Size Figure Download Figure

Figure 1 Flowchart of study participants. CHB: Chronic hepatitis B; TAF: Tenofovir alafenamide; ETV: Entecavir; TCHO: Total cholesterol; HDL: High density lipoprotein; LDL: Low-density lipoprotein; TG: Triglycerides.

Citation: Lai RM, Lin S, Wang MM, Li N, Zhou JH, Lin XY, Chen TB, Zhu YY, Zheng Q. Tenofovir alafenamide significantly increased serum lipid levels compared with entecavir therapy in chronic hepatitis B virus patients. World J Hepatol 2023; 15(8): 964-972
URL: https://www.wjgnet.com/1948-5182/full/v15/i8/964.htm
DOI: https://dx.doi.org/10.4254/wjh.v15.i8.964